Drugs / EVO101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06645821 | Dec 2024 → Mar 2025 overdue | hidradenitis suppurativa | Virginia Clinical Research, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05579899 | Sep 2022 → Jul 2023 | atopic eczema | Evommune, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVO101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06645821 ↗ |
| Route | Topical | “This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.” NCT05579899 ↗ |